GlassScriptPhysician profile
Ignacio D Velazquez
NPI 1972923290
$2,153.06
in general payments reported to CMS, 2019-2025
26 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $202 · 2021: $291 · 2022: $195 · 2023: $599 · 2024: $315 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,014.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $251.81 | 2021-2024 | |
| Boston Scientific Corporation | $242.42 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $220.95 | 2023-2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $220.46 | 2023-2024 | Xarelto |
| Pfizer INC. | $193.45 | 2019-2024 | |
| Amgen INC. | $159.01 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $142.36 | 2020-2025 | Lifevest |
| Abbott Laboratories | $138.67 | 2019-2022 | |
| Scpharmaceuticals INC. | $70.13 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $60.36 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.53 | 2023-2024 | Jardiance |
| Heartflow, INC. | $57.73 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $52.67 | 2024 | Arcalyst |
| Astellas Pharma US INC | $45.26 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $30.23 | 2023 | Arcalyst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $28.10 | 2021 | |
| Medtronic Vascular, INC. | $27.69 | 2020 | |
| Getinge USA Sales, LLC | $26.60 | 2020 | |
| Lantheus Medical Imaging, INC. | $24.28 | 2023 | Definity |
| Sanofi-Aventis U.S. LLC | $23.72 | 2019 | |
| United Therapeutics Corporation | $23.45 | 2023 | Tyvaso |
| Alnylam Pharmaceuticals INC. | $19.96 | 2019 | |
| Terumo Medical Corporation | $17.90 | 2020 | |
| Chiesi USA, INC. | $16.32 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ignacio Velazquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.